803 results on '"Dhruva, Sanket S."'
Search Results
152. Protocol for project recovery after cardiac surgery: a single-center cohort study leveraging digital platform to characterise longitudinal patient-reported postoperative recovery patterns
153. The Art of the Deal: Negotiating Consult Conflict
154. Early experience with the FDA’s Breakthrough Devices program
155. Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shock—Reply
156. Tu1145 ENDOSCOPIC TRANSMISSION OF CARBEPENEM-RESISTANT ENTEROBACTERIACEAE: FDA APPROVAL AND POST-MARKETING SURVEILLANCE OF ENDOSCOPIC DEVICES
157. Clinical Evidence Supporting FDA Clearance of First-of-a-Kind Therapeutic Devices via the De Novo Pathway Between 2011 and 2019
158. Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials—a brave new world
159. A Successful but Underused Strategy for Reducing Low-Value Care: Stop Paying for It
160. 2019 Update on Pediatric Medical Overuse
161. Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender Individuals
162. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
163. Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
164. Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data
165. Physician and Patient Adjustment to Reference Pricing for Drugs
166. Protocol for Project Recovery: Cardiac Surgery - Leveraging Digital Platform for Efficient Collection of Longitudinal Patient-Reported Outcome Data Towards Improving Postoperative Recovery
167. Accelerated Approval and Possible Withdrawal of Midodrine
168. Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews
169. Aggregating Multiple Real-World Data Sources using a Patient-Centered Health Data Sharing Platform: an 8-week Cohort Study among Patients Undergoing Bariatric Surgery or Catheter Ablation of Atrial Fibrillation
170. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings
171. 2019 Update on Medical Overuse
172. Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics
173. Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016
174. Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence
175. Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment
176. Evidence Strength in FDA Premarket Approval of Cardiovascular Devices—Reply
177. CMSʼs Landmark Decision on CT Colonography
178. Variations Between Clinical Trial Participants and Medicare Beneficiaries in Evidence Used for Medicare National Coverage Decisions
179. Prescription Digital Therapeutics: The Authors Reply
180. Moving From Substantial Equivalence to Substantial Improvement for 510(k) Devices
181. Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT
182. Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies
183. Controversies in Diagnostic Imaging of Patients With Suspected Stable and Acute Chest Pain Syndromes
184. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
185. Evaluation of technologies approved for supplemental payments in the United States
186. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
187. Clinical Interpretation of High-Sensitivity Troponin Testing—Reply
188. Abstract 119: Using the VA National Cardiac Device Surveillance Program to Monitor the Safety of Cardiovascular Implantable Electronic Devices
189. 2018 Update on Pediatric Medical Overuse
190. Abstract 216: Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies after Guideline Revisions
191. Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017
192. Implementation of an EConsult System with Patient Navigation
193. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval
194. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
195. Alirocumab’s Price Reduction
196. Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program
197. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016
198. Unique Device Identifiers for Medical Devices at 10 Years
199. For the Patient with “Low-risk Chest Pain”—How Low Is Low?
200. Changing FDA Approval Standards: Ethical Implications for Patient Consent.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.